Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
Status:
Recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
This study is an open-label, single arm, multicenter, roll-over extension study to
characterize long-term safety, tolerability and efficacy of iptacopan and to provide access
to iptacopan to patients with PNH who have completed Novartis-sponsored Phase 2 or 3 studies
with iptacopan